Biotech Volatile Stocks: OXiGENE Inc (NASDAQ:OXGN), Immunomedics, Inc. (NASDAQ:IMMU), BioCryst Pharmaceuticals (NASDAQ:BCRX), ZIOPHARM Oncology (NASDAQ:ZIOP)

Posted by on Apr 24, 2014

OXiGENE, Inc (NASDAQ:OXGN) a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first quarter 2014 results on Tuesday May 6, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT). OXiGENE Inc (NASDAQ:OXGN) shares after opening at $3.13 moved to $3.30 on last trade day and at the end of the day closed at $3.24 . Company price to sales ratio in past twelve months was calculated as 520.11 and price to cash ratio as 7.06. OXiGENE Inc (NASDAQ:OXGN) showed a positive weekly performance of 19.56%.

Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. (NASDAQ:IMMU) common stock between May 9, 2013 and October 9, 2013. Immunomedics, Inc. (NASDAQ:IMMU) shares fell -9.19% in last trading session and ended the day on $4.15. IMMU return on equity ratio is recorded as -37.10% and its return on assets is -30.90%. Immunomedics, Inc. (NASDAQ:IMMU) yearly performance is 63.39%.

Analysts at Brinson Patrick started coverage on shares of BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX) in a research report issued to clients and investors on Monday,TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $15.00 price target on the stock. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares moved down -7.07% in last trading session and was closed at $8.55 while trading in range of $8.40 – $9.23 – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) year to date (YTD) performance is 12.50%.

ZIOPHARM Oncology, Inc (NASDAQ:ZIOP) announced the presentation of data from a study demonstrating the anti-tumor effects and tolerability of Ad-RTS-mIL-12 in a glioblastoma (brain cancer) murine model. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled, local expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) weekly performance is 9.58%. On last trading day company shares ended up $3.66. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) distance from 50-day simple moving average (SMA50) is -15.50%. Analysts mean target price for the company is $6.69.

Leave a Reply

Your email address will not be published. Required fields are marked *